Sidley represented ReCode Therapeutics in the fundraising. ReCode Therapeutics announced the closing of an extension to its Series B financing. The extension raised an additional $50...
ReCode Therapeutics’ $50 Million Series B Financing Extension
ADARx Pharmaceuticals’ $200 Million Series C Financing Round
Sidley Austin represented ADARx Pharmaceuticals in the financing. ADARx Pharmaceuticals, Inc. announced its successful close of an oversubscribed $200 million Series C financing. The proceeds from...
Lepu Biopharma and Keymed Biosciences’ Licensing Agreement with AstraZeneca AB
Zhong Lun advised Lepu Bio on the deal while Sidley represented Keymed Biosciences. Lepu Biopharma Co., Ltd and Keymed Biosciences Inc. signed a global exclusive license agreement...
ADARx Pharmaceuticals’ US$46 Million Series B-1 Financing
Sidley represented ADARx Pharmaceuticals, Inc. on the deal. ADARx Pharmaceuticals, Inc., a clinical-stage biotechnology company developing RNA-targeting therapeutics, announced its US$46 million Series B-1 financing. The proceeds...
Crown Bioscience’s Acquisition of Indivumed’s CRO Services Business
Freshfields Bruckhaus Deringer advised Indivumed GmbH on the deal while Sidley is represented Crown Bioscience. Indivumed GmbH sold its “IndivuServ” business unit to a wholly owned...
Akeso’s US$5 Billion Licensing Agreement With Summit Therapeutics Title
Sidley advised Akeso Inc. on the deal. Akeso Inc. announced a high-profile US$5 billion collaboration and licensing agreement with Summit Therapeutics Inc. to out-license its breakthrough bispecific...
Grab’s $40 Billion Merger with Altimeter Capital
Cooley LLP advised J.P. Morgan, Morgan Stanley, UBS and Evercore on the deal. Ropes & Gray and Wilmer Cutler Pickering Hale and Dorr LLP advised Altimeter,...